Global Anti-obesity Drugs Market 2018-2022 - Product Image

Global Anti-obesity Drugs Market 2018-2022

  • ID: 4703279
  • Report
  • Region: Global
  • 99 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5
The research on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic obesity and type 2 diabetes is increasing. This demands for increasing focus on the drugs that can control obesity and diabetes. Analysts have predicted that the anti-obesity drugs market will register a CAGR of almost 8% by 2023.

Market Overview

Global increase in both incidence and prevalence of obesity

The prevalence and incidence rate of obesity is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the shoot in the rates of obesity across the world offers huge opportunities for drug manufacturing vendors to manufacture innovative and highly effective drugs.

Limited reimbursement for anti-obesity drugs

Although US is the major market for anti-obesity drugs, the challenges associated with the reimbursement of these drugs is more in the US. The bariatric surgery can recover weight related issues and is life-saving, but the concern for financial burden remains. People are unwilling to pay for this surgery as they believe that obesity is a cosmetic or lifestyle issue, which led player limit coverage.

For the detailed list of factors that will drive and challenge the growth of the anti-obesity drugs market during the 2018-2022, view the report.

Competitive Landscape

The market appears to be concentrated and with the presence of few companies including Eisai and Novo Nordisk the competitive environment is quite intense. Factors such as the increase in childhood obesity incidence and the use of implantable neuroregulatory devices for treating obesity, will provide considerable growth opportunities to anti-obesity drugs manufactures. Eisai, Novo Nordisk, and Vivus are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market to witness the presence of a few international and regional anti-obesity drug companies who offer obesity treatment drugs for mechanism such as centrally-acting and peripherally-acting anti-obesity drugs.’
READ MORE
Note: Product cover images may vary from those shown
2 of 5
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: PIPELINE ANALYSIS
  • Pipeline analysis
PART 08: MARKET SEGMENTATION BY DRUGS BASED ON CLASS OF OBESITY
  • Segmentation by drugs based on class of obesity
  • Comparison by drugs based on class of obesity
  • Class I anti-obesity drugs - Market size and forecast 2017-2022
  • Class II anti-obesity drugs - Market size and forecast 2017-2022
  • Class III anti-obesity drugs - Market size and forecast 2017-2022
  • Market opportunity by drugs based on class of obesity
PART 09: MARKET SEGMENTATION BY MECHANISM OF ACTION
  • Segmentation by mechanism of action
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Research on drugs that target both obesity and type 2 diabetes mellitus
  • Increase in childhood obesity incidence
  • Use of implantable neuroregulatory devices for treating obesity
  • Increase in morbid obesity incidence
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eisai
  • Novo Nordisk
  • Vivus
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global metabolic disorder therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Drugs based on class of obesity - Market share 2017-2022 (%)
Exhibit 19: Comparison by drugs based on class of obesity
Exhibit 20: Class I anti-obesity drugs - Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Class I anti-obesity drugs - Year-over-year growth 2018-2022 (%)
Exhibit 22: Class II anti-obesity drugs - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Class II anti-obesity drugs - Year-over-year growth 2018-2022 (%)
Exhibit 24: Class III anti-obesity drugs - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Class III anti-obesity drugs - Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by drugs based on class of obesity
Exhibit 27: Customer landscape
Exhibit 28: Global - Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 32: Top three countries in Americas
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: Top three countries in EMEA
Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 38: Top three countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: List of target drugs for obesity and type 2 diabetes mellitus
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Eisai - Overview
Exhibit 47: Eisai - Business segments
Exhibit 48: Eisai - Organizational developments
Exhibit 49: - Geographic focus
Exhibit 50: Eisai - Key offerings
Exhibit 51: Novo Nordisk - Overview
Exhibit 52: Novo Nordisk - Business segments
Exhibit 53: Novo Nordisk - Organizational developments
Exhibit 54: Novo Nordisk - Geographic focus
Exhibit 55: Novo Nordisk - Segment focus
Exhibit 56: Novo Nordisk - Key offerings
Exhibit 57: Vivus - Overview
Exhibit 58: Vivus - Business segments
Exhibit 59: Vivus - Organizational developments
Exhibit 60: Vivus - Geographic focus
Exhibit 61: Vivus - Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
The author of the report recognizes the following companies as the key players in the global anti-obesity drugs market: Eisai, Novo Nordisk, and Vivus.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the research on drugs that target obesity and type 2 diabetes mellitus.”

According to the report, one of the major drivers for this market is the Global increase in both incidence and prevalence of obesity.

Further, the report states that one of the major factors hindering the growth of this market is the Limited reimbursement for anti-obesity drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Eisai
  • Novo Nordisk
  • Vivus
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4703279
Adroll
adroll